DOXORUBICIN CLEARANCE IN THE OBESE

被引：169

作者：

RODVOLD, KA

RUSHING, DA

TEWKSBURY, DA

机构：

[1] UNIV ILLINOIS,COLL PHARM,CLIN PHARMACOKINET LAB,CHICAGO,IL 60612

[2] MARSHFIELD CLIN,DEPT MED ONCOL,MARSHFIELD,WI 54449

[3] MARSHFIELD MED FDN INC,MARSHFIELD,WI 54449

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1988年 / 6卷 / 08期

关键词：

D O I：

10.1200/JCO.1988.6.8.1321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1321 / 1327

页数：7

共 32 条

[1] THE INFLUENCE OF OBESITY ON THE PHARMACOKINETICS OF ORAL ALPRAZOLAM AND TRIAZOLAM [J].

ABERNETHY, DR ;

GREENBLATT, DJ ;

DIVOLL, M ;

SMITH, RB ;

SHADER, RI .

CLINICAL PHARMACOKINETICS, 1984, 9 (02) :177-183

[2] OBESITY, SEX, AND ACETAMINOPHEN DISPOSITION [J].

ABERNETHY, DR ;

DIVOLL, M ;

GREENBLATT, DJ ;

AMEER, B .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (06) :783-790

[3]

ABERNETHY DR, 1981, J PHARMACOL EXP THER, V217, P681

[4] FATTY LIVER HEPATITIS AND CIRRHOSIS IN OBESE PATIENTS [J].

ADLER, M ;

SCHAFFNER, F .

AMERICAN JOURNAL OF MEDICINE, 1979, 67 (05) :811-816

[5]

BACHUR NR, 1977, CLIN PHARMACOL THER, V21, P70

[6]

BACHUR NR, 1979, CANCER TREAT REP, V63, P817

[7]

BENJAMIN RS, 1974, CANCER, V33, P19, DOI 10.1002/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO

[8]

2-M

[9]

BENJAMIN RS, 1973, CLIN PHARMACOL THER, V14, P592

[10]

BERKOWITZ D, 1964, JAMA-J AM MED ASSOC, V187, P399

← 1 2 3 4 →